Boehringer Ingelheim

This early-stage study tested a new drug called BI 765883, given alone or with chemotherapy, for people with advanced pancreatic cancer that had spread or returned after surgery. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early after…

This study tested whether adding an experimental pill (BI 706321) to the standard Crohn's drug ustekinumab could better control moderate to severe Crohn's disease. About 49 adults were randomly assigned to receive either the combination or a placebo plus ustekinumab for 3 months,…

This study looked at the safety and effectiveness of Pradaxa oral pellets for treating blood clots or preventing them from coming back in children aged 3 months to 12 years. The study was stopped early and only enrolled 6 participants. It aimed to track bleeding events and other …

This study tested a new drug, BI 907828, in adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplified, TP53 normal). Participants took a pill every three weeks. The trial was stopped early, but researchers were c…

This study tested a new medicine, BI 765845, in adults who recently had a heart attack. Participants received either the medicine or a placebo, and doctors monitored heart health over 3 months. The study was terminated early, so results are limited.

This study looked at how safe and helpful the drug spesolimab is over a long period for people with hidradenitis suppurativa (HS), a painful skin condition. It included 39 adults who had already completed a prior spesolimab study. Participants received injections every two weeks …

This study looked at the long-term safety of the drug iclepertin in adults with schizophrenia who had already completed earlier trials. Participants took iclepertin once a day for one year, along with their usual schizophrenia medication. The study was terminated early, but the g…

This study looks at the long-term safety of spesolimab in people with palmoplantar pustulosis, a painful skin condition causing blisters on hands and feet. Participants who saw improvement in earlier spesolimab trials can join and receive monthly injections for up to 5 years. Doc…

This study tested a new medicine called Avenciguat (BI 685509) to lower high blood pressure in the liver's main vein, a condition called portal hypertension, in people with compensated cirrhosis. About 90 adults with cirrhosis from hepatitis B, C, or NASH took the drug alone or w…

This study tested a medicine called spesolimab in people aged 12 and older with Netherton syndrome, a rare genetic skin condition causing redness and scaling. Participants received either the drug or a placebo for 4 months, then everyone could get the drug. The goal was to see if…

This study looked at whether a medicine called Avenciguat could lower high blood pressure in the main vein to the liver in adults with cirrhosis. Participants took either a low or high dose of the drug or a placebo twice a day for 24 weeks. The trial was terminated early, so resu…

This study tested an experimental drug called BI 1839100 to see if it could reduce chronic coughing in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants took different doses of the drug or a placebo for 12 weeks. Coughing was me…

This early-stage study looked at how healthy men absorb, break down, and eliminate the experimental drug BI 1839100. In one part, participants took the drug by mouth and researchers measured how much came out in urine and stool. In another part, the drug was given both by mouth a…

This study looks at how healthy men absorb, break down, and eliminate a drug called BI 1819479. It has two parts: one tracks the drug's radioactivity in urine and stool, and the other compares a tablet form to a low-dose injection. The goal is to understand the drug's behavior in…

This early-stage study tested a single dose of the experimental drug BI 1569912 in 68 healthy men to see if it is safe and how the body processes it. The study also looked at how food affects the drug's absorption. The trial was terminated early, so results are limited.

This early-stage study aimed to check the safety and how the body handles multiple doses of an experimental drug called BI 3731579. It involved 30 healthy adults aged 18 to 55 who took the drug or a placebo daily for 15 days. The trial was terminated early, so results are limited…

This study looked at how safe a new drug, BI 706321, is and how it moves through the body in healthy Japanese and Chinese men. The trial was stopped early. It involved 48 participants and was designed to gather safety information, not to treat any disease.

This early-stage study aimed to check the safety and how the body handles a new experimental drug called BI 3009947 in healthy men. It also compared two different pill versions of the drug and looked at how food affects one of them. The study was stopped early and involved 40 par…

This early-phase study used special PET scans to see where an experimental drug (BI 754111) goes in the body and how much reaches tumors in people with advanced non-small cell lung cancer or head/neck cancer. Only 8 participants were enrolled before the study was stopped. The mai…